Bikesh Kumar Nirala

Dr. Bikesh Kumar Nirala

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
BNBikesh Kumar Nirala
Bikesh Kumar Nirala
TYTaku Yamamichi
Taku Yamamichi
DPD. Isabel Petrescu
D. Isabel Petrescu
TSTasnuva N. Shafin
Tasnuva N. Shafin
Jason YusteinJason Yustein
Jason Yustein
Osteosarcoma (OS) is a heterogeneous, highly metastatic bone malignancy in children and adolescents. Despite advancements in multimodal treatment strategies, the prognosis for patients with metastatic or recurrent disease has not improved significantly in the last four decades. OS is a highly heterogeneous tumor; its genetic background and the mechanism of oncogenesis are not well defined. Unfortunately, no effective molecular targeted therapy is currently available for this disease. Understanding osteosarcoma’s tumor microenvironment (TME) has recently gained much interest among scientists hoping to provide valuable insights into tumor heterogeneity, progression, metastasis, and the identification of novel therapeutic avenues. Here, we review the current understanding of the TME of OS, including different cellular and noncellular components, their crosstalk with OS tumor cells, and their involvement in tumor progression and metastasis. We also highlight past/current clinical trials targeting the TME of OS for effective therapies and potential future therapeutic strategies with negligible adverse effects.

Verified
Journal Article
Open access
PDF file
BNBikesh Kumar Nirala
Bikesh Kumar Nirala
TYTaku Yamamichi
Taku Yamamichi
Jason YusteinJason Yustein
Jason Yustein
Osteosarcoma (OS) is the predominant primary bone tumor in the pediatric and adolescent populations. It has high metastatic potential, with the lungs being the most common site of metastasis. In contrast to many other sarcomas, OS lacks conserved translocations or genetic mutations; instead, it has heterogeneous abnormalities, including somatic DNA copy number alteration, ploidy, chromosomal amplification, and chromosomal loss and gain. Unfortunately, clinical outcomes have not significantly improved in over 30 years. Currently, no effective molecularly targeted therapies are available for this disease. Several genomic studies showed inactivation in the tumor suppressor genes, including p53, RB, and ATRX, and hyperactivation of the tumor promoter genes, including MYC and MDM2, in OS. Alterations in the major signaling pathways, including the PI3K/AKT/mTOR, JAK/STAT, Wnt/β-catenin, NOTCH, Hedgehog/Gli, TGF-β, RTKs, RANK/RANKL, and NF-κB signaling pathways, have been identified in OS development and metastasis. Although OS treatment is currently based on surgical excision and systematic multiagent therapies, several potential targeted therapies are in development. This review focuses on the major signaling pathways of OS, and we propose a biological rationale to consider novel and targeted therapies in the future.

11 May 2015 in Diabetes & Vascular Disease Research
Verified
Journal Article
Open access
BNBikesh Kumar Nirala
Bikesh Kumar Nirala
VPVivekanandan Perumal
Vivekanandan Perumal
NGNivedita K Gohil
Nivedita K Gohil
Pro-inflammatory conditions induced by products of protein glycation in diabetes substantially enhance the risk of endothelial dysfunction and related vascular complications. Endothelial cell specific molecule-1 (ESM-1) or endocan has been demonstrated as a potential biomarker in cancer and sepsis. Its role in diabetes-induced pathologies remains unknown. The expression of ESM-1 gene is under cytokine regulation, indicating its role in endothelium-dependent pathological disorders. In this study, we investigated the effect of advanced glycated human serum albumin (AGE-HSA) on the production of ESM-1. We show that AGE-HSA exerts a modulating role on the expression of ESM-1 in human umbilical vein endothelial cells. It up-regulates expression of ESM-1 protein in a dose-dependent manner which correlates with its messenger RNA (mRNA) transcription. RAGE and galectin-3, both AGE receptors, show antagonistic action on its expression. While gene silencing of RAGE has down-regulatory effect, that of galectin-3 has up-regulatory effect on AGE-induced expression of ESM-1. Inhibition of MAPKKK and JNK pathways did not alter the expression. In contrast, phosphatidylinositol 3 kinase (PI3K) inhibition significantly up-regulated ESM-1 expression. In conclusion, these results suggest that AGE-induced activation of human umbilical vein endothelial cells promotes formation of endocan which is an endothelial dysfunction marker and may be related to vascular disease in diabetes.

28 April 2008 in Journal of Environmental Science and Health, Part A
Verified
Journal Article
Closed access
ATAmit Kumar Tyagi
Amit Kumar Tyagi
BNBikesh Kumar Nirala
Bikesh Kumar Nirala
AMAnushree Malik
Anushree Malik
KSKamlesh Singh
Kamlesh Singh
Antibacterial activity of negative air ions (NAI) on Escherichia coli and Pseudomonas fluorescens has been investigated. Appropriately diluted cell suspensions of E. coli and P. fluorescens were inoculated onto agar and exposed to NAI (> 2 × 106 ions/cm3) in an airtight chamber. Although no bacterial killing was observed after short exposure (15–30 min), longer exposure upto 4 hours caused 33% and 42% reduction in viability of E. coli and P. fluorescens, respectively. Maximum killing was observed when the plates were positioned in front of the NAI generator. Young exponential phase cells of P. fluorescens were more resistant (8% reduction in viability) as compared to stationary phase cells (42% reduction in viability). Also, the starved cells displayed less reduction in viability (33%) as compared to normal cells (42%). The susceptibility of bacterial strains to NAI varies depending upon the strain type, their physiological state as well as the distance/orientation with respect to the source. Although application of NAI for decreasing the ambient microbial load is a valid option; extended exposures might be required for controlling physiologically different cells such as exponential phase cells and/or starved cells.

23 September 2025 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
BNBikesh Kumar Nirala
Bikesh Kumar Nirala
Jason YusteinJason Yustein
Jason Yustein
Cancer continues to be a significant global health issue, influenced by genetic mutations and external factors like carcinogenic exposure, lifestyle choices, and chronic inflammation. The myelocytomatosis (MYC) oncogene family, including c-MYC, MYCN, and MYCL, is essential in the development, progression, and metastasis of various cancers such as breast, colorectal, osteosarcoma, and neuroblastoma. Beyond its well-known roles in cell growth and metabolism, MYC significantly shapes the tumor immune microenvironment (TIME) by altering immune cell dynamics, antigen presentation, and checkpoint expression. It contributes to immune evasion by upregulating checkpoints such as programmed death-ligand 1 (PD-L1) and cluster of differentiation (CD)47, suppressing antigen-presenting major histocompatibility complex (MHC) molecules, and promoting the recruitment of suppressive immune cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). While direct targeting of MYC has proven challenging, recent advances in therapeutic strategies, including MYC-MYC-associated factor X (MAX) dimerization inhibitors, bromodomain and extra terminal domain (BET) and cyclin dependent kinase (CDK) inhibitors, synthetic lethality approaches, and epigenetic modulators, have shown promising results in preclinical and early clinical settings. This review discusses MYC’s comprehensive impact on TIME and examines the promising therapeutic strategies of MYC inhibition in enhancing the effectiveness of immunotherapies, supported by recent preclinical and clinical findings.

1 December 2013 in Advanced Materials Letters
Verified
Journal Article
Closed access
HKHarminder Kaur
Harminder Kaur
GPGeetanjali Pujari
Geetanjali Pujari
ASAsitikantha Sarma
Asitikantha Sarma
Yogendra MishraYogendra Mishra
Yogendra Mishra
MJMi Kyung Jin
Mi Kyung Jin
DADevesh Kumar Avasthi
Devesh Kumar Avasthi